SequelSEC

STANDARD BIOTOOLS INC. LAB

Pharmaceutical Preparations · CIK 0001162194 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$20.10M
Fiscal year ended 2026-06-30
Operating income
-$25.39M
Fiscal year ended 2026-06-30
Free cash flow
-$10.66M
Fiscal year ended 2026-06-30

STANDARD BIOTOOLS INC. (LAB) reported revenue of $20.10M and net income of -$26.76M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from STANDARD BIOTOOLS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

STANDARD BIOTOOLS INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$20.10M$21.15M$23.80M$19.55M$21.76M$20.22M$24.78M$22.09M$22.49MUnavailable
Cost of revenue$9.57M$9.84M$12.41M$10.07M$11.13M$9.17M$13.42M$9.96M$12.12MUnavailable
Gross profit$10.54M$11.31M$11.38M$9.48M$10.63M$11.05M$11.36M$12.13M$10.37MUnavailable
Operating income-$25.39M-$12.50M-$24.64M-$32.94M-$25.70M-$26.97M-$26.08M-$26.70M-$30.26MUnavailable
Net income-$26.76M$127.07M$19.28M-$34.69M-$33.46M-$26.03M-$34.07M-$26.94M-$45.72MUnavailable
Research & development$1.98M$2.12M$7.97M$6.36M$6.22M$5.44M$7.04M$6.94M$7.24MUnavailable
Weighted-average diluted sharesshares 390.88Mshares 388.20MUnavailableshares 382.63Mshares 380.50Mshares 378.23MUnavailableshares 371.54Mshares 372.33MUnavailable
Pretax income-$21.44M-$14.62M-$22.03M-$32.90M-$18.28M-$23.49M-$26.90M-$21.80M-$25.40MUnavailable
Income tax expense$90.00K$11.00K-$35.93M-$1.22M-$609.00K-$119.00K$272.00K$118.00K$39.00KUnavailable
Diluted EPS$-0.07$0.33Unavailable$-0.09$-0.09$-0.07Unavailable$-0.07$-0.12Unavailable
Selling, general & administrative$16.39M$18.61M$25.34M$26.60M$28.10M$29.82M$27.32M$24.47M$24.86MUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

STANDARD BIOTOOLS INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$270.03M$265.77M$120.86M$129.42M$158.62M$150.88M$166.73M$210.65M$269.81MUnavailable
Total assets$627.22M$639.11M$567.75M$539.64M$556.96M$579.60M$612.34M$681.54M$708.73MUnavailable
Current assets$516.87M$521.45M$454.26M$472.44M$506.04M$344.02M$375.88M$453.61M$480.03MUnavailable
Total liabilities$87.25M$77.99M$143.46M$139.98M$132.43M$125.00M$140.62M$192.21M$198.47MUnavailable
Current liabilities$56.80M$42.20M$108.31M$107.96M$98.02M$56.24M$65.90M$120.62M$123.81MUnavailable
Total equity incl. NCI$539.97M$561.12M$424.29M$399.66M$424.54M$454.60M$471.72M$489.33M$510.26MUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0Unavailable
Inventory$17.10M$18.59M$19.98M$25.42M$24.17M$42.12M$20.74M$42.64M$42.62MUnavailable
Accounts receivable$15.75M$16.64M$13.43M$13.54M$14.61M$35.48M$14.74M$35.32M$32.44MUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable$111.72M$111.30M$106.34M$106.25MUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$299.00K$55.21M$55.08MUnavailable
Accounts payable$9.55M$8.01M$5.41M$6.62M$7.33M$11.78M$5.05M$10.93M$12.57MUnavailable

Cash flow

STANDARD BIOTOOLS INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$10.31M-$46.60M-$1.19M-$22.20M-$20.67M-$30.28M-$14.06M-$27.87M-$39.05MUnavailable
Capital expenditures$344.00K$570.00K$476.00K$886.00K$1.89M$5.05M$3.38M$2.26M$1.94MUnavailable
Investing cash flow$14.41M$191.09M-$8.04M-$6.68M$27.50M$14.62M$25.73M-$30.88M$50.26MUnavailable
Financing cash flow-$138.00K-$40.00K$620.00K-$112.00K$108.00K-$46.00K-$54.52M-$2.00K-$28.36MUnavailable
Net change in cash$4.25M$144.57M-$8.71M-$29.20M$7.73M-$15.35M-$43.12M-$59.16M-$17.24MUnavailable
Stock-based compensation$4.05M$8.82M$5.74M$8.47M$6.39M$9.01M$7.47M$5.92M$6.73MUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$0$0$0$0$0$0$29.44MUnavailable
Depreciation & amortization$1.27M$1.41M$1.29M$1.52M$3.18M$3.27M$3.14M$3.86M$3.86MUnavailable

Derived

STANDARD BIOTOOLS INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$10.66M-$47.17M-$1.67M-$23.09M-$22.56M-$35.34M-$17.44M-$30.12M-$40.99MUnavailable
Gross margin52.4%53.5%47.8%48.5%48.8%54.6%45.8%54.9%46.1%Unavailable
Operating margin-126.3%-59.1%-103.6%-168.5%-118.1%-133.4%-105.3%-120.9%-134.5%Unavailable
FCF margin-53.0%-223.1%-7.0%-118.1%-103.6%-174.7%-70.4%-136.4%-182.2%Unavailable
SBC / revenue20.1%41.7%24.1%43.3%29.3%44.6%30.1%26.8%29.9%Unavailable
Current ratio9.10x12.36x4.19x4.38x5.16x6.12x5.70x3.76x3.88xUnavailable
Revenue YoY growth-7.6%4.6%-4.0%-11.5%-3.2%Unavailable-12.1%-12.9%-18.7%Unavailable
Net margin-133.1%Unavailable81.0%-177.4%-153.7%Unavailable-137.5%-122.0%UnavailableUnavailable
R&D / revenue9.8%10.0%33.5%32.5%28.6%26.9%28.4%31.4%32.2%Unavailable
CapEx / revenue1.7%2.7%2.0%4.5%8.7%25.0%13.6%10.2%8.6%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LAB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-15View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.